Why the study?
Does a sirolimus-eluting stent prevent neointimal proliferation, restenosis, and associated clinical events compared to a standard coronary stent in patients requiring coronary revascularization?
Does a sirolimus-eluting stent prevent neointimal proliferation, restenosis, and associated clinical events compared to a standard coronary stent in patients requiring coronary revascularization?
A sirolimus-eluting stent shows promise in preventing restenosis and clinical events compared to standard stents for coronary revascularization.
Sirolimus-eluting stents merit first-line consideration to curb restenosis; extends bare-metal stent data with RCT-level support for drug-eluting platforms.
As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.
No takes yet. Share an insight, caveat, or question.
Morice et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: